COMMUNIQUÉS West-GlobeNewswire

InnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2025
06/05/2025
DENVER, May 06, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
Amwell makes grant to new employee under inducement plan
06/05/2025
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading technology-enabled care platform provider, announced that on May 6, Amwell made a grant of RSUs of 3,451 shares of its Class A common stock to [...]
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
06/05/2025
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin ( [...]
Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance
06/05/2025
First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-year First quarter 2025 Total revenues of $462 million, up 33% year-over-year Medicare Advantage medical costs are in line with expectations [...]
Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025
06/05/2025
IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter [...]
WW International, Inc. Announces First Quarter 2025 Results
06/05/2025
Total End of Period Subscribers of 3.4 million, including 135 thousand End of Period Clinical Subscribers Revenues of $186.6 million, down 9.7% vs. prior year period, including Clinical Subscription Revenues of $29.5 [...]
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
06/05/2025
LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06/05/2025
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]
Voyager Reports First Quarter 2025 Financial and Operating Results
06/05/2025
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on [...]
Standard BioTools Reports First Quarter 2025 Financial Results
06/05/2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. [...]
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
06/05/2025
– Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 – WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra [...]
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3
06/05/2025
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated [...]
Late-Breaking Interim STENOVA Data Presented at Digestive Disease Week® 2025 Demonstrate Potential of AGMB-129 in Fibrostenosing Crohn’s Disease
06/05/2025
Antwerp, Belgium, May 6, 2025 – Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA 1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted [...]
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
06/05/2025
HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the [...]
Annual NMDP(SM) Gala in New York City Raises Over a Half Million Dollars, Enabling More Patients to Receive Life-Saving Cell Therapy
06/05/2025
MINNEAPOLIS, May 06, 2025 (GLOBE NEWSWIRE) -- NMDP SM hosted its annual gala in New York on Thursday, May 1, raising $525,000-- funds which will support patient financial assistance and innovative cell therapy research [...]
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
06/05/2025
CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of [...]
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
06/05/2025
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
06/05/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 6 mai 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général [...]
EssilorLuxottica: Disclosure of transactions in own shares
06/05/2025
Disclosure of transactions in own shares Paris, France (May 6, 2025 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2024, EssilorLuxottica declares that on [...]

Pages